← FDA DRUG APPROVALS

FDA ANDA · ANDA075271

CROMOLYN SODIUM

Sponsor: TEVA PHARMS

APPLICATION
ANDA075271
TYPE
ANDA
ORIGINAL APPROVAL
2000-01-18
LATEST ACTION
2025-10-02
ROUTE
INTRABRONCHIAL, INHALATION
DOSAGE FORM
SOLUTION
MARKETING STATUS
Prescription

Products

CROMOLYN SODIUMPrescription
CROMOLYN SODIUM 10MG/ML · SOLUTION · INHALATION

Approval history

2025-10-02Manufacturing (CMC) · Supplement 14 · unknownAP
2008-09-03Labeling · Supplement 7AP
2001-08-15Labeling · Supplement 2AP
2001-08-15Manufacturing (CMC) · Supplement 1AP
2000-01-18OriginalReviewAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →